Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) (“
Innate” or the “
Company”)
today announced the publication of a Nature paper entitled,
“Association of COVID-19 inflammation with activation of the
C5a-C5aR1 axis,” authored by Innate researchers in partnership with
scientists from Hôpitaux Universitaires de Marseille AP-HM (La
Timone and North Hospitals), Laveran Hospital, Aix Marseille
University, the Centre d’Immunologie de Marseille-Luminy (Inserm,
CNRS, AMU) and Marseille Immunopole/AP-HM immunoprofiling
laboratory at La Timone Hospital.
This Marseille-based exploratory research
taskforce, named EXPLORE COVID-19, analyzed immune cells in
COVID-19 patients at different stages of the disease. The goal of
the study was to gain translational insights to better understand
the immune response in COVID-19 patients and identify potential
targets to fight the viral infection.
The study found that patients who progress
towards severe COVID-19 disease, including those with severe
pneumonia and acute respiratory distress syndrome (ARDS), exhibit
an activation of the C5a/C5aR1 pathway. Specifically, researchers
observed high levels of circulating C5a and over-activation of the
C5a-dependent myeloid cell pathway, which is believed to contribute
to inflammation in the lungs.
This research also focused on avdoralimab
(IPH5401), a clinical-stage monoclonal antibody that blocks C5aR1
(CD88). Avdoralimab prevents C5a-induced myeloid cell recruitment
and activation. Innate is currently investigating avdoralimab in
oncology, which provided pharmacokinetic and safety data prior to
investigation in COVID-19.
The findings published in Nature suggest that
the C5a-C5aR1 axis blockade could be considered as a potential
therapeutic strategy for severe respiratory disease associated with
SARS-Cov-2 infection. The analysis found the C5a-C5aR1 axis
blockade as a means of limiting myeloid cell infiltration at
inflammatory sites and preventing the excessive lung inflammation
associated with ARDS in COVID-19 patients.
“There is an urgent need to better understand
COVID-19 disease progression and the associated complement cascade
to help improve the prognosis of COVID-19 patients who present
severe symptoms,” said Pr. Eric Vivier, PhD, Chief
Scientific Officer at Innate Pharma and Professor at AP-HM,
Aix-Marseille University and Centre d’Immunologie de
Marseille-Luminy (Inserm/CNRS/AMU). “We
are encouraged by this exploratory study, as we’re beginning to
understand the impact of the immune response on the evolution of
COVID-19 and pathways able to modulate this response.”
Based on findings from this study, the Company
previously announced the launch of an investigator-sponsored trial
named FORCE (FOR COVID-19 Elimination). This is a randomized,
double-blind Phase II clinical trial to further explore avdoralimab
in COVID-19 patients with severe pneumonia, which is currently
ongoing.
You can read the full publication in Nature
here.
About the EXPLORE COVID-19
study:
Researchers analyzed the immune response of
COVID-19 patients with no or few symptoms, patients who require
oxygen, and a group of severe patients who require prolonged
mechanical ventilation. The study included 82 individuals: 10
healthy controls and 72 COVID-19 patients, including 10 patients
presenting few symptoms, 34 patients with pneumonia, and 28
patients with ARDS.
Avdoralimab in cancer:
Avdoralimab is a therapeutic antibody that
specifically binds and blocks C5a receptor 1 (C5aR1) expressed on
myeloid cells, including monocytes, macrophages and
neutrophils. It is currently in Phase I development in solid
tumors, including hepatocellular carcinoma and non-small cell lung
cancer.
Avdoralimab in COVID-19:
C5a has been implicated in the pathogenesis of
ARDS by promoting a proinflammatory environment, through the
attraction of myeloid cells (neutrophils, monocytes and
macrophages) and the stimulation of their cytokines production.
Avdoralimab blocks C5aR1 and has the potential to reduce the
inflammatory response in the lungs.
About Innate Pharma:
Innate Pharma S.A. is a commercial stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product,
Lumoxiti, in-licensed from AstraZeneca in the US, EU and
Switzerland, was approved by the FDA in September 2018. Lumoxiti is
a first-in class specialty oncology product for hairy cell
leukemia. Innate Pharma’s broad pipeline of antibodies includes
several potentially first-in-class clinical and preclinical
candidates in cancers with high unmet medical need.
Innate Pharma has been a pioneer in the
understanding of natural killer cell biology and has expanded its
expertise in the tumor microenvironment and tumor-antigens, as well
as antibody engineering. This innovative approach has resulted in a
diversified proprietary portfolio and major alliances with leaders
in the biopharmaceutical industry including Bristol-Myers Squibb,
Novo Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Based in Marseille, France, Innate Pharma is
listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995.The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts,
the Company’s continued ability to raise capital to fund its
development and the overall impact of the COVID-19 outbreak on the
global healthcare system as well as the Company’s business,
financial condition and results of operations. For an
additional discussion of risks and uncertainties which could cause
the company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2019,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Investors Innate Pharma
Tel.: +33 (0)4 30 30 30 30investors@innate-pharma.com
|
Media Innate Pharma Tracy
Rossin (Global/US)Tel.: +1 240 801
0076Tracy.Rossin@innate-pharma.com
ATCG Press Marie Puvieux (France)Tel.: +33 (0)9 81
87 46 72innate-pharma@atcg-partners.com |
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024